Amylyx Co-CEO sells 15,500 shares for taxes

Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen reported an automatic sale of common stock to cover taxes.

Rhea-AI Filing Summary

Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen reported an automatic sale of common stock to cover taxes. On February 2, 2026, he sold 15,500 shares of Amylyx common stock at a weighted average price of $14.6834 per share.

The footnotes explain that these shares were required to be sold to satisfy tax withholding obligations from vested restricted stock units and were not sold at his discretion. After this tax-related sale, Cohen beneficially owned 3,363,965 shares of Amylyx common stock in direct ownership.

Insider Trade Summary

Net Seller: 15,500 shares

Net Sell 1 txn

Insider Cohen Joshua B

Role Co-Chief Executive Officer

Sold 15,500 shs ($228K)

Type	Security	Shares	Price	Value
Sale	Common Stock	15,500	$14.6834	$228K

Holdings After Transaction: Common Stock — 3,363,965 shares (Direct)

Footnotes (2)

1. F1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.510 to $14.760. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Amylyx (AMLX) report for Joshua B. Cohen?

Amylyx reported that Co-Chief Executive Officer Joshua B. Cohen sold 15,500 shares of common stock. The sale occurred on February 2, 2026 and was made to cover tax withholding obligations related to the vesting of restricted stock units, according to the filing’s footnote.

Why did Amylyx (AMLX) Co-CEO Joshua B. Cohen sell 15,500 shares?

The 15,500 shares were sold to satisfy tax withholding obligations triggered by the vesting of restricted stock units. The filing states these tax-related sales were automatic and not at Cohen’s discretion, meaning they occurred as part of standard equity compensation tax processing.

At what price were Joshua B. Cohen’s Amylyx (AMLX) shares sold?

The shares were sold at a weighted average price of $14.6834 per share. The document notes that the transactions occurred in multiple trades at prices ranging between $14.510 and $14.760, with detailed trade breakdowns available to SEC staff upon request.

How many Amylyx (AMLX) shares does Joshua B. Cohen own after this transaction?

Following the reported sale, Joshua B. Cohen beneficially owned 3,363,965 shares of Amylyx common stock. The filing identifies these shares as directly held, giving a post-transaction snapshot of his reported ownership position after the tax-related sale.

Was the Amylyx (AMLX) insider sale discretionary or automatic?

The sale was automatic rather than discretionary. The footnote explains that the shares were required to be sold to cover tax withholding obligations arising from restricted stock unit vesting, indicating the transaction followed predefined tax settlement procedures instead of a voluntary open-market decision.

What role does Joshua B. Cohen hold at Amylyx (AMLX)?

Joshua B. Cohen is identified as both a director and Co-Chief Executive Officer of Amylyx Pharmaceuticals, Inc. This dual role is explicitly checked in the filing’s relationship section, confirming his leadership and board responsibilities in connection with the reported equity transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Joshua B

(Last) (First) (Middle)

C/O AMYLYX PHARMACEUTICALS, INC.

55 CAMBRIDGE PARKWAY, SUITE 6W

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amylyx Pharmaceuticals, Inc. [ AMLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		S(1)		15,500(1)	D	$14.6834(2)	3,363,965	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.510 to $14.760. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

	/s/ Joshua B. Cohen	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.